Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇯🇵JP · Science#1961K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 5K🎙 Weekly cadence·48 episodes·Last published 3w ago - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 10K🇯🇵100% - Active Followers
Loyal subscribers who consistently listen
400 to 4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Apr 27, 2026
57m 26s
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Apr 17, 2026
27m 12s
Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
Feb 27, 2026
59m 42s
Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Dec 17, 2025
57m 46s
Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dec 12, 2025
1h 43m 11s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/27/26 | EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | EGFR mutationnon-small cell lung cancer+3 | Dr Suresh S RamalingamDr Helena Yu | EGFRnon-small cell lung cancer | — | EGFR mutationnon-small cell lung cancer+3 | — | 57m 26s | |
| 4/17/26 | Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays✨ | lung cancercirculating tumor DNA+3 | Dr Natalie Vokes | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | lung cancercirculating tumor DNA+3 | — | 27m 12s | |
| 2/27/26 | Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy✨ | lung cancersmall cell lung cancer+3 | Dr Hossein BorghaeiDr Anne Chiang | Fox Chase Cancer CenterYale Cancer Center | Philadelphia, PennsylvaniaNew Haven, Connecticut | extensive-stage small cell lung cancerfirst-line management+3 | — | 59m 42s | |
| 12/17/25 | Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy✨ | small cell lung cancerfirst-line therapy+3 | Dr Luis Paz-AresDr Shields | Spanish National Oncology Research CenterIndiana University School of Medicine | — | extensive-stagesmall cell lung cancer+4 | — | 57m 46s | |
| 12/12/25 | Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network✨ | lung cancertreatment landscape+3 | Dr Justin F GainorDr Corey J Langer+1 | American Oncology Network | — | lung cancertreatment+3 | — | 1h 43m 11s | |
| 12/10/25 | HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach✨ | HER2-altered non-small cell lung cancertreatment strategies+3 | Dr John Heymach | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | HER2non-small cell lung cancer+3 | — | 1h 05m 13s | |
| 11/10/25 | Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerantibody-drug conjugates+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 21m 21s | |
| 10/20/25 | Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerTROP2+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 24m 47s | |
| 9/14/25 | Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerTROP2-directed antibody-drug conjugates+3 | Dr Jacob Sands | Dana-Farber Cancer Institute | Boston, Massachusetts | lung cancerTROP2+4 | — | 23m 19s | |
| 8/22/25 | Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases✨ | small cell lung cancertherapies+3 | Dr Stephen V LiuDr Charles Rudin | Georgetown University HospitalMemorial Sloan Kettering Cancer Center | Washington, DCNew York | small cell lung cancertherapies+3 | — | 58m 18s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/18/25 | Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates | Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 8/8/25 | Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances | Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here. | — | ||||||
| 7/17/25 | Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates | Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here. | — | ||||||
| 7/8/25 | For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
| 6/20/25 | EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting | Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here. | — | ||||||
| 6/10/25 | Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances | Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 5/18/25 | Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit | Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. CME information and select publications here. | — | ||||||
| 4/30/25 | EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit | Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 4/26/25 | For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
| 4/10/25 | First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor | Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 12/13/24 | Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer | Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer. | — | ||||||
| 12/11/24 | Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer | Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer. | — | ||||||
| 11/25/24 | The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences | Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer. | — | ||||||
| 11/16/24 | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Lung Cancer | Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer. | — | ||||||
Showing 24 of 49
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.